Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07544680 · ClinicalTrials.gov registry record
Endometrial Cancer Vaginal Fluid Specimen Collection Study
A clinical trial, sponsored by Exact Sciences Corporation.
- Recruiting
- Registry status
- 4,200
- Enrollment target
NCT07544680: Recruiting study, sponsored by Exact Sciences Corporation.
NCT07544680 is a clinical trial that is actively recruiting participants, run by Exact Sciences Corporation. The registered enrollment target is 4,200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07544680 is actively recruiting participants, sponsored by Exact Sciences Corporation.
- RECRUITING
- Registry status
- 4,200 participants
- Enrollment target
Study Summary
This is a multicenter, prospective, specimen collection study for development and evaluation of tests used to detect endometrial cancer, other cancers, or their causes.
Primary Outcome
Vaginal fluid specimens will be collected during a standard clinical exam using a swab-based collection method. Specimens will be used for research purposes to support the development of biomarker assays. No specific biomarkers or analytical methods are defined as part of this study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,200 participants |
| Start Date | 2026-03-10 |
| Est. Completion | 2028-04-24 |
What NCT07544680 shows while recruiting
NCT07544680 is an observational study that tracks outcomes without assigning an intervention. Its 4,200 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07544680 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07544680 about?
NCT07544680 is a clinical study titled "Endometrial Cancer Vaginal Fluid Specimen Collection Study". This is a multicenter, prospective, specimen collection study for development and evaluation of tests used to detect endometrial cancer, other cancers, or their causes.
What is the current status of trial NCT07544680?
This trial is currently recruiting. The enrollment target is 4,200 participants. The study started on 2026-03-10. Estimated completion is 2028-04-24.
Who is sponsoring clinical trial NCT07544680?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- NCT05969028 · 4,200 participants · NA
First Responder Airway & Compression Rate Trial
- NCT06935370 · 4,200 participants · Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
- NCT07209098 · 4,200 participants
Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI